Literature DB >> 14752840

The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa.

Gregory D Kirk1, Olufunmilayo A Lesi, Maimuna Mendy, Aliu O Akano, Omar Sam, James J Goedert, Pierre Hainaut, Andrew J Hall, Hilton Whittle, Ruggero Montesano.   

Abstract

Hepatocellular carcinoma (HCC) is the most common cancer in The Gambia. Hepatitis B virus (HBV) infection is endemic, with 15% to 20% of the population being chronic carriers, whereas hepatitis C virus (HCV) prevalence is low. We recruited 216 incident cases of HCC and 408 controls from three sites. HBV carriage was present in 61% (129/211) of HCC patients and 16% (64/402) of controls, whereas 19% (36/191) of HCC patients were HCV seropositive compared with 3% (11/382) of controls. HCC patients with HCV were notably older and were more likely to be female than those with HBV. Increased HCC risk was strongly associated with chronic HBV (odds ratio, 16.7; 95% CI, 9.7-28.7), HCV (16.7; 6.9-40.1), and dual infection (35.3; 3.9-323). We interpret the additive nature of risk with coinfection as representative of HBV and HCV acting primarily through shared steps in the multistage process of hepatocarcinogenesis. HCV infection was not observed among younger participants, suggesting a possible cohort effect. Reasons for the striking age and gender differences in HCC associated with HBV compared with HCV are unclear, but transmission patterns and age at exposure may be factors. In conclusion, in a standardized evaluation of well-characterized study participants from The Gambia, most cases of HCC are attributable to HBV (57%), but HCV adds a significant fraction (20%), especially among older patients and females. If HCV transmission is not perpetuated in future cohorts, focusing available resources on HB vaccination efforts could greatly ameliorate a major cause of cancer death in sub-Saharan Africa.

Entities:  

Mesh:

Year:  2004        PMID: 14752840     DOI: 10.1002/hep.20027

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  69 in total

Review 1.  Vaccination greatly reduces disease, disability, death and inequity worldwide.

Authors:  F E Andre; R Booy; H L Bock; J Clemens; S K Datta; T J John; B W Lee; S Lolekha; H Peltola; T A Ruff; M Santosham; H J Schmitt
Journal:  Bull World Health Organ       Date:  2008-02       Impact factor: 9.408

Review 2.  Global HBV burden: guesstimates and facts.

Authors:  Dina Ginzberg; Robert J Wong; Robert Gish
Journal:  Hepatol Int       Date:  2018-07-27       Impact factor: 6.047

3.  Screening and treatment of hepatitis B virus to prevent liver cancer in Africa.

Authors:  Mark R Thursz
Journal:  Hepat Oncol       Date:  2015-04-20

4.  A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours.

Authors:  Xiaoyu Li; Meng Qiu; Li Zheng; ShengJun Wang; Hong Zhu; Bi Feng
Journal:  Cancer Chemother Pharmacol       Date:  2020-02-01       Impact factor: 3.333

Review 5.  KASL clinical practice guidelines: management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

6.  Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States.

Authors:  Ju Dong Yang; Sean F Altekruse; Mindie H Nguyen; Gregory J Gores; Lewis R Roberts
Journal:  Cancer       Date:  2016-08-29       Impact factor: 6.860

7.  Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment.

Authors:  Yan Liu; Felicia Wu
Journal:  Environ Health Perspect       Date:  2010-02-19       Impact factor: 9.031

8.  Combined effect of socioeconomic status, viral hepatitis, and lifestyles on hepatocelluar carcinoma risk in Korea.

Authors:  E H Yun; M K Lim; J-K Oh; J H Park; A Shin; J Sung; E-C Park
Journal:  Br J Cancer       Date:  2010-07-20       Impact factor: 7.640

Review 9.  Meeting the global demands of epidemiologic transition - the indispensable role of cancer prevention.

Authors:  Silvia Franceschi; Christopher P Wild
Journal:  Mol Oncol       Date:  2012-11-17       Impact factor: 6.603

10.  Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa.

Authors:  M E Mendy; T Welzel; O A Lesi; P Hainaut; A J Hall; M H Kuniholm; S McConkey; J J Goedert; S Kaye; S Rowland-Jones; H Whittle; G D Kirk
Journal:  J Viral Hepat       Date:  2009-10-27       Impact factor: 3.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.